New Crown Outbreak: 27.29 million! Sanofi/Regenerative IL-6 inhibitor Kevzara treats (critical) critically ill patients with Phase III clinical failure!

September 07, 2020 / / -- At present, the outbreak of new crown pneumonia abroad is still spreading rapidly.
according to Baidu's Real-Time Big Data Report on the Outbreak of New Coronavirus Pneumonia, as of 12 p.m. on September 7, 2020, there were more than 27.29 million confirmed cases and more than 887,000 deaths worldwide.
recently, Sanofi released the latest results from a global Phase III clinical trial outside the United States to evaluate the treatment of severe and critically ill COVID-19 hospitalized patients with the anti-inflammatory drug Kevzara.
The study was conducted in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia and Spain and included 420 patients (86 in the placebo group, 161 in the Kevzara 200mg dose group and 173 in the 400 mg dose group).
study, Kevzara or placebo was added to routine medical care.
results showed that Kevzara did not reach the primary and critical secondary endpoints compared to the placebo.
although there was no statistically significant difference, numerical trends were observed in shorter hospital stays and faster improvement in clinical outcomes (measured by a baseline improvement of 2 points on the 7-part scale).
.
, a trend of reduced mortality was observed in critically ill patients, but not in severe patient groups.
, the discharge time of patients treated with Kevzara was reduced by 2-3 days (statistically not significant) during the first 2 weeks of treatment.
safety, 26-29% of Kevzara patients and 24% of placebo patients had severe adverse events.
in all three treatment groups, the risk of adverse events leading to death was about 10 per cent.
infections, including COVID-19 pneumonia, occurred in 11-13% of Kevzara patients and 12% of placebo patients.
details of the study will be published later this year in a peer-reviewed journal.
, Sanofi and Regenerative Cell are not expected to conduct further clinical studies of Kevzara's treatment of COVID-19. Dr John Reed, head of global research and development at
Sanofi, said: "While this trial did not produce the results we had hoped for, we are proud of the team's work, which has further deepened our understanding of the potential use of Kevzara's treatment COVID-19.
Sanofi, we are committed to helping fight the global COVID-19 pandemic, including the development of vaccine candidates for mass production.
" Kevzara was developed by Sanofi in collaboration with Regeneratives, a monoclonal antibody that inhibits IL-6-mediated signaling by targeting binding and blocking IL-6 subjects (IL-6R).
IL-6 is a cytokine associated with a variety of inflammatory diseases, and IL-6 is the most abundant cytokine in ra's serums and fluids, with levels closely related to disease activity and joint damage.
Kevzara was developed by Regeneron using its proprietary Veloclmmune antibody technology to block the binding of IL-6 to IL-6R and interrupt the IR-6-mediated inflammatory cascading response.
, Kevzara has been approved in several countries for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have no response or tolerance to previous treatments.
() Origin: Sanofi provides update on Kevzara? (sarilumab) Phase 3 trial in severe and critically ill COVID-19 patients outside the U.S.